ArticleBMC pediatrics2026
Unveiling the unexpected: refractory rickets as an uncommon presentation of tyrosinemia type I.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyrosinemia type I is a rare autosomal recessive inborn error of metabolism caused by deficiency of fumarylacetoacetate hydrolase (FAH), an enzyme essential for the final breakdown of tyrosine. The enzyme defect leads to accumulation of toxic metabolites, primarily affecting the liver, kidneys, and brain. Typically, diagnosed in infancy due to acute or chronic liver dysfunction, refractory rickets is an uncommon presentation. We report a child with tyrosinemia type I presenting with refractory rickets and hepatosplenomegaly but with preserved liver function. CASE PRESENTATION: A three-year-old child presented with bilateral limb deformities unresponsive to multiple courses of vitamin D and calcium. The child also exhibited floppiness, polyuria, and polydipsia. Evaluation revealed hepatomegaly and hypophosphatemic rickets secondary to Fanconi syndrome, later confirmed to be due to tyrosinemia type I. The child was treated with phosphate supplementation, nitisinone, and a tyrosine- and phenylalanine-restricted diet, with favorable follow-up.
conclusionTyrosinemia type I may present beyond infancy with renal-predominant manifestations such as refractory rickets and preserved hepatic function. Early diagnosis and treatment are essential to prevent progression and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.